Shattuck Labs Inc (STTK)

$0.96 -0.02 (-1.80%)
Market Cap 45.84M
Revenue (ttm) 5.72M
Net Income (ttm) -75.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,318.36%
Debt to Equity Ratio 0.00
Volume 108,500
Avg Vol 116,992
Day's Range N/A - N/A
Shares Out 47.90M
Stochastic %K 5%
Beta 1.72
Analysts Sell
Price Target $3.00

Company Profile

Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease; and a series of bispecific antibodies targeting DR3 and other clinically val...

Industry: Biotechnology
Sector: Healthcare
Phone: 512 900 4690
Address:
500 West 5th Street, Suite 1200, Austin, United States
JAG_2_Trade
JAG_2_Trade May. 28 at 12:38 PM
$STTK Shattuck Labs First Quarter 2025 Earnings: US$0.27 loss per share (vs US$0.37 loss in 1Q 2024) And the stock goes up, earnings is good but the stock dips. Why?
0 · Reply
JAG_2_Trade
JAG_2_Trade May. 23 at 5:37 PM
$STTK declined earning report, but today, it's going up. I don't get it.
0 · Reply
bioebi
bioebi Apr. 8 at 10:01 PM
$IBG $AGH $IBO $STTK IBG is next after AGH
0 · Reply
cofhu12twits
cofhu12twits Apr. 8 at 4:02 PM
$STTK Great setup here
0 · Reply
NextBigRun
NextBigRun Apr. 7 at 9:17 PM
GLXG can see a massive multiple dollar move into tomorrow! $BJDX $CHSN $STTK $MESA $NWTG !!!..
0 · Reply
KUMU
KUMU Apr. 7 at 8:29 PM
$STTK went short here off algo trap 1.40
0 · Reply
IntraTrades
IntraTrades Apr. 7 at 8:05 PM
$MKDW 188.89% $DFDV 164.19% $STTK 82.84% $ARTV 44.54% $SPAI 43.29%
0 · Reply
Origin4494
Origin4494 Apr. 7 at 8:02 PM
$CHSN $SVRE $STTK Pops at close
1 · Reply
Benbobaggins
Benbobaggins Apr. 7 at 7:56 PM
$STTK still in the beginning of the rise. Get early shares to get the most out of it $AREB $BIAF $RSLS
0 · Reply
Pwist
Pwist Apr. 7 at 7:54 PM
$YXT NEXT 🚀 $MLGO $DFDV $MKDW $STTK
0 · Reply
Latest News on STTK
Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025, 4:20 PM EDT - 7 weeks ago

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 5:00 PM EDT - 2 months ago

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Mar 27, 2025, 7:00 AM EDT - 3 months ago

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Feb 20, 2025, 9:00 AM EST - 4 months ago

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Feb 13, 2025, 4:30 PM EST - 4 months ago

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress

Feb 4, 2025, 7:00 AM EST - 4 months ago

Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress

Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 4:59 PM EST - 5 months ago

Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025

Jan 2, 2025, 7:00 AM EST - 6 months ago

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025

Shattuck Labs, Inc. (STTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Oct 29, 2024, 10:00 AM EDT - 8 months ago

Shattuck Labs, Inc. (STTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Shareholders to Inquire about Securities Investigation

Oct 28, 2024, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Shareholders to Connect

Oct 27, 2024, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Investors to Connect

Oct 23, 2024, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Stockholders to Inquire about Securities Investigation

Oct 22, 2024, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Shattuck Labs, Inc. (STTK) and Encourages Investors to Learn More About the Investigation

Oct 21, 2024, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Shattuck Labs, Inc. (STTK) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Stockholders to Connect

Oct 20, 2024, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Stockholders to Connect

Shattuck Labs, Inc. (STTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Oct 16, 2024, 10:00 AM EDT - 8 months ago

Shattuck Labs, Inc. (STTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Shattuck Labs, Inc. (STTK) and Encourages Stockholders to Learn More About the Investigation

Oct 15, 2024, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Shattuck Labs, Inc. (STTK) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Investors to Inquire about Securities Investigation

Oct 14, 2024, 6:00 PM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Investors to Inquire about Securities Investigation

Shattuck Labs' stock craters as biotech scraps main product candidate after failed trial

Oct 1, 2024, 12:23 PM EDT - 9 months ago

Shattuck Labs' stock craters as biotech scraps main product candidate after failed trial

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

Oct 1, 2024, 6:30 AM EDT - 9 months ago

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference

Jul 30, 2024, 5:00 PM EDT - 11 months ago

Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference

Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes

Jul 1, 2024, 6:00 AM EDT - 1 year ago

Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leuk

Jun 14, 2024, 6:00 AM EDT - 1 year ago

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leuk

Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)

Jun 10, 2024, 7:30 AM EDT - 1 year ago

Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)

Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk My

Jun 6, 2024, 7:30 AM EDT - 1 year ago

Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk My

Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the E

May 14, 2024, 4:15 PM EDT - 1 year ago

Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the E

Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 2, 2024, 7:05 AM EDT - 1 year ago

Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights

Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024

Apr 9, 2024, 4:05 PM EDT - 1 year ago

Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024

Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference

Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D.

Mar 4, 2024, 7:00 AM EST - 1 year ago

Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D.

Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Feb 29, 2024, 4:05 PM EST - 1 year ago

Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Shattuck Labs Announces Participation in Upcoming March Conferences

Feb 26, 2024, 7:00 AM EST - 1 year ago

Shattuck Labs Announces Participation in Upcoming March Conferences

Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins

Feb 14, 2024, 5:06 AM EST - 1 year ago

Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins

Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases

Feb 13, 2024, 6:00 AM EST - 1 year ago

Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024

Jan 8, 2024, 7:00 AM EST - 1 year ago

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024

Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference

Jan 4, 2024, 4:05 PM EST - 1 year ago

Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference

Shattuck Labs: Positive Blood Cancer Data Leads To Mid-2024 Catalyst

Dec 21, 2023, 6:58 PM EST - 1 year ago

Shattuck Labs: Positive Blood Cancer Data Leads To Mid-2024 Catalyst

Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

Dec 21, 2023, 8:00 AM EST - 1 year ago

Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Pat

Dec 13, 2023, 6:00 AM EST - 1 year ago

Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Pat

Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Da

Dec 5, 2023, 4:15 PM EST - 1 year ago

Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Da

Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference

Nov 14, 2023, 9:00 AM EST - 1 year ago

Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference

JAG_2_Trade
JAG_2_Trade May. 28 at 12:38 PM
$STTK Shattuck Labs First Quarter 2025 Earnings: US$0.27 loss per share (vs US$0.37 loss in 1Q 2024) And the stock goes up, earnings is good but the stock dips. Why?
0 · Reply
JAG_2_Trade
JAG_2_Trade May. 23 at 5:37 PM
$STTK declined earning report, but today, it's going up. I don't get it.
0 · Reply
bioebi
bioebi Apr. 8 at 10:01 PM
$IBG $AGH $IBO $STTK IBG is next after AGH
0 · Reply
cofhu12twits
cofhu12twits Apr. 8 at 4:02 PM
$STTK Great setup here
0 · Reply
NextBigRun
NextBigRun Apr. 7 at 9:17 PM
GLXG can see a massive multiple dollar move into tomorrow! $BJDX $CHSN $STTK $MESA $NWTG !!!..
0 · Reply
KUMU
KUMU Apr. 7 at 8:29 PM
$STTK went short here off algo trap 1.40
0 · Reply
IntraTrades
IntraTrades Apr. 7 at 8:05 PM
$MKDW 188.89% $DFDV 164.19% $STTK 82.84% $ARTV 44.54% $SPAI 43.29%
0 · Reply
Origin4494
Origin4494 Apr. 7 at 8:02 PM
$CHSN $SVRE $STTK Pops at close
1 · Reply
Benbobaggins
Benbobaggins Apr. 7 at 7:56 PM
$STTK still in the beginning of the rise. Get early shares to get the most out of it $AREB $BIAF $RSLS
0 · Reply
Pwist
Pwist Apr. 7 at 7:54 PM
$YXT NEXT 🚀 $MLGO $DFDV $MKDW $STTK
0 · Reply
AnarchoTrader
AnarchoTrader Apr. 7 at 7:53 PM
$STTK AH runner
1 · Reply
Benbobaggins
Benbobaggins Apr. 7 at 7:53 PM
$STTK $BIAF $AREB $DFDV $RSLS join for the next run at $STTK 🔥🔥🔥🔥
0 · Reply
Dieseld28
Dieseld28 Apr. 7 at 7:53 PM
$STTK
0 · Reply
Benbobaggins
Benbobaggins Apr. 7 at 7:43 PM
$STTK taking 20% profit made from $AREB and $DFDV into $STTK
0 · Reply
Dieseld28
Dieseld28 Apr. 7 at 5:47 PM
$STTK $10 soon like $DFDV
0 · Reply
BigSqueezeComing
BigSqueezeComing Apr. 7 at 5:40 PM
$STTK I have loaded up more on this stock. lets go
0 · Reply
BearishAlgo
BearishAlgo Apr. 7 at 4:48 PM
$STTK That was quick
0 · Reply
BearishAlgo
BearishAlgo Apr. 7 at 4:47 PM
$STTK stop loss 1.08, TP 0.88 area
0 · Reply
BearishAlgo
BearishAlgo Apr. 7 at 4:46 PM
$STTK short sell zone 0.98- 1.08
0 · Reply
Dieseld28
Dieseld28 Apr. 7 at 4:44 PM
$DFDV $STTK
0 · Reply
Dieseld28
Dieseld28 Apr. 7 at 3:12 PM
$STTK wen $1
0 · Reply